Aptevo Therapeutics Receives Orphan Drug Designation for APVO436 for the Treatment of Acute Myelogenous Leukemia
December 06, 2019 09:00 ET
|
Aptevo Therapeutics Inc.
SEATTLE, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, announced today that the...
Aptevo Therapeutics and Alligator Bioscience Present New Preclinical Data for ALG.APV-527 at the Society for Immunotherapy of Cancer 2019 Annual Meeting
November 08, 2019 09:00 ET
|
Aptevo Therapeutics Inc.
Preclinical Data Show That ALG.APV-527 is Well Tolerated with Repeated Dosing Preliminary in vivo Data Show that ALG.APV-527 has Potent Anti-tumor Activity and Induces an Immunological Memory...
Aptevo Therapeutics Reports Third Quarter 2019 Financial Results
November 07, 2019 09:00 ET
|
Aptevo Therapeutics Inc.
Reports Record Net Revenue for IXINITY; Achieves 55% Increase in Year-over-Year Quarterly Net Revenue Advances APVO436 Phase 1/1b Clinical Study in AML/MDS SEATTLE, Nov. 07, 2019 (GLOBE NEWSWIRE)...
Aptevo Therapeutics Provides Corporate and Pipeline Update
October 03, 2019 16:02 ET
|
Aptevo Therapeutics Inc.
Reports Record Quarterly IXINITY® Net Revenue and New Patient Conversions Following Launch of New 3,000 IU Assay Provides Update on Ongoing APVO436 Phase 1/1b Clinical Study;Evidence of Potential...
Aptevo Therapeutics Introduces New Adaptir™ Bispecific Antibody Candidate Intended for the Treatment of Solid Tumors
September 19, 2019 09:00 ET
|
Aptevo Therapeutics Inc.
New ADAPTIR Candidate APVO603 is a Dual-Agonistic BispecificAntibody Targeting 4-1BB and OX40 APVO603 is Designed to Induce Synergistic Effects on Immune Responseswith Potential to Enhance...
Aptevo Therapeutics Reports Second Quarter 2019 Financial Results
August 09, 2019 09:00 ET
|
Aptevo Therapeutics Inc.
Reports Positive Preliminary Top-Line Safety Data for APVO210Phase 1 Single Ascending Dose (SAD) Clinical Study Advances APVO210 into Phase 1 Multiple Ascending Dose (MAD) Study Commences Dosing...
Aptevo Therapeutics Receives $4.3 Million Milestone Payment From Saol International Limited
August 07, 2019 09:02 ET
|
Aptevo Therapeutics Inc.
SEATTLE, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, announced today the...
Aptevo Therapeutics Reports Continued Progress In APVO210 and APVO436 Clinical Trials
July 25, 2019 16:32 ET
|
Aptevo Therapeutics Inc.
Completes Dosing in Single Ascending Dose (SAD) Phase 1 Study of APVO210 Receives Approval to Begin APVO210 Multiple Ascending Dose (MAD) Study Preliminary Data Suggest that Single Doses of APVO210...
Aptevo Therapeutics Launches New 3000 IU IXINITY Assay Offering Enhanced User Experience and Improved Convenience for Hemophilia B Patients
June 25, 2019 09:00 ET
|
Aptevo Therapeutics Inc.
Expands Options for Patients with Potential for Reduced Reconstitution Time and Infusion Volume SEATTLE, June 25, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a...
Aptevo Therapeutics Reports First Quarter 2019 Financial Results
May 09, 2019 09:00 ET
|
Aptevo Therapeutics Inc.
Achieves 73% Increase in First Quarter 2019 Year-Over-Year IXINITY® Net Revenue On Target for Launch of New 3,000 IU IXINITY Assay Mid-2019 Advances Enrollment in APVO436 and APVO210 Phase 1...